Physician profile
Mohit Jhamb
NPI 1295969731
$7,734.75
in general payments reported to CMS, 2019-2025
15 companies · $3,050 in 2025
The $3,050 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $169 · 2021: $1,285 · 2022: $1,153 · 2023: $776 · 2024: $646 · 2025: $3,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,029 · Consulting Fee: $1,996 · Travel and Lodging: $448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,028.85 |
| Consulting Fee | $1,995.50 |
| Travel and Lodging | $447.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $3,000.40 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,801.68 | 2019-2024 | Xarelto |
| Vifor Pharma, INC. | $846.45 | 2020-2023 | Veltassa |
| Amgen INC. | $523.37 | 2021-2024 | Repatha |
| Travere Therapeutics, INC. | $346.82 | 2022-2024 | |
| Shionogi INC | $314.71 | 2021-2025 | Fetroja |
| Dexcom, INC. | $237.96 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.30 | 2025 | Jardiance |
| Nestle Healthcare Nutrition INC. | $125.00 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $120.84 | 2019 | |
| Novo Nordisk INC | $120.79 | 2025 | Ozempic |
| Novartis Pharmaceuticals Corporation | $90.79 | 2024 | |
| Alexion Pharmaceuticals, INC. | $19.99 | 2024 | Ultomiris |
| Ucb, INC. | $16.32 | 2024 | Briviact |
| Digestive Care, INC. | $11.33 | 2025 | Pertzye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohit Jhamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.